Cadence Pharmaceuticals, Inc. (CADX) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CADX Hot Sheet
Price: $13.98 --0%
Financial Fact:
Total costs and expenses: 38.31M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Total costs and expenses: 38.31M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $14.16 million.
As of November 5, 2012, Cadence expects that net product revenue from sales of OFIRMEV for the three months ending December 31, 2012, will range from approximately $15.9 million to $16.4 million.
For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.
As of November 5, 2012, Cadence expects that net product revenue from sales of OFIRMEV for the three months ending December 31, 2012, will range from approximately $15.9 million to $16.4 million.
For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
